Navigation Links
Novel enzyme inhibitor paves way for new cancer drug
Date:5/15/2008

have proven useful as therapeutic agents, he says.

To overcome this hurdle and develop an inhibitor with greater specificity, and therefore greater potential as a drug candidate, Marmorstein and his colleagues set out to create a lipid kinase inhibitor using a metal complex in its structure.

Though most protein inhibitors are created using purely organic atomssuch as carbon, nitrogen, oxygen and sulfuradding a metal to the mix allows one to create compounds that are otherwise impossible to make with a purely organic toolbox, Marmorstein says.

The metal not only lends a structural support to the inhibitor but also provides the ability to form and accept a wider range of ligands, or chemical building blocks, to increase kinase selectivity, he says.

Working with Eric Meggers of the University of Pennsylvania (now at the Philipps-Universtat Marburg in Germany), who has developed organometallic enzyme inhibitors for other types of kinases, the scientists combined traditional organic compounds with the metal Ruthenium to create a novel scaffold, the platform on which the inhibitor was constructed.

After screening a general organometallic library of compounds designed by Meggers to identify potential agents to inhibit PI3K, the scientists identified a protein kinase inhibitor known as DW2.

The scientists then used X-ray crystallography to determine the three-dimensional structure of PI3K bound to DW2, using the structure as a starting point to fashion more effective PI3K inhibitors.

Based on what they had observed in their structural studies, the scientists were able to make several changes to the inhibitor to prepare a more potent and selective agent, Marmorstein says.

To determine how well their new inhibitor, called E5, could selectively target PI3K lipid kinases, the researchers tested the agent on five different human protein kinases representing four kinase families. The study showed E5 selec
'/>"/>

Contact: Abbey J. Porter
aporter@wistar.org
215-898-3943
The Wistar Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
2. Novel mechanisms controlling insulin release and fat deposition discovered
3. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
4. Discovery of a novel mechanism for the development of colon cancer
5. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
6. Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
7. Scientists identify novel way to prevent cardiac fibrosis
8. Registry unveils real-world data on novel excel stent
9. Researchers sharpen search for new marine medicines with novel techniques
10. Increased hepcidin expression: A novel oncogenic signalling mechanism
11. Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 When struck with the ... to know where to begin. The latest eBook ... accident attorney, offers accident victims a clear and concise ... to ensure their personal injury claim is seen through ... the first actions that should be taken immediately following ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... Industry is a professional and in-depth study on ... market with a focus on the Chinese ... of the industry including definitions, classifications, applications and ... provided for both the international and Chinese domestic ...
(Date:3/27/2015)... RI (PRWEB) March 27, 2015 April 2015 ... war – the Sesquicentennial. To honor America’s bloodiest war and ... Fort Adams Trust presents A Tribute to the Civil War ... PM, Friday, April 17, 2015, at the Jane Pickens Theater ... noted Civil War-Lincoln scholar, will serve as the master of ...
(Date:3/27/2015)... March 27, 2015 The ... Quaker-based, philanthropic, grant-making foundation committed to raising its ... healthcare is delivered. , The Scattergood Foundation and ... Behavioral Health Policy and Practice through the Annual ... Program App is designed to guide the ...
(Date:3/26/2015)... March 26, 2015 Alliance Healthcare Foundation ... and wellness for the poor and underserved in San ... for its annual $1 million award, the Innovation Initiative ... announce the 2015 round of our Innovation Initiative Award,” ... supported some incredibly creative and ambitious projects in the ...
Breaking Medicine News(10 mins):Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 2Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 3Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 4Health News:SoundsLikeIBS Nominated For 3rd Annual Scattergood Innovation Award 2Health News:Applications Open for $1M Innovation Initiative Award from Alliance Healthcare Foundation 2
... Gerresheimer Stock in the SDAX as Per September 6, 2007 ... Outside the Normal Schedule, ... 5 September, DÜSSELDORF, Germany, September 3 Gerresheimer AG has,been listed ... following one of the largest IPOs of the year, with a total,issue ...
... we all know that tall parents are more likely to ... common genes that make people taller than others. Now, however, ... common variant of which directly influences height. , The ... the variant and a person carrying no copies is just ...
... 31, 2007) Two worldwide studies published in this week,s ... chronic obstructive pulmonary disease (COPD). The only U.S. site in ... in Eastern Kentucky, and was found to have some of ... fact, it had the second highest rate among women and ...
... designed for brain tumour therapy has shown promising tumour ... by scientists at The University of Nottingham. The project, ... and Human Development, will be featured in the September ... for brain cancers is particularly difficult for a number ...
... in on diacetyl, a key component of butter flavoring in ... key chemical ingredient in the buttery flavoring of microwave popcorn ... a lung disease that afflicts people who work in the ... Publishing in the September issue of the American Journal ...
... smoking are more likely to have sleep disturbances such ... sleep duration, and snoring loudly or breathing uncomfortably, according ... of the journal SLEEP. , The study, authored by ... focused on the responses of 16,396 and 19,386 pregnant ...
Cached Medicine News:Health News:High and mighty: first common height gene identified by researchers behind 'obesity gene' finding 2Health News:High and mighty: first common height gene identified by researchers behind 'obesity gene' finding 3Health News:Two studies published in the Lancet 2Health News:Novel 3-D cell culture model shows selective tumour uptake of nanoparticles 2Health News:Scientists ID Likely Culprit in 'Popcorn Lung' 2Health News:Passive smoking increases sleep disturbance among pregnant women 2
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
(Date:3/26/2015)... and VANCOUVER, British Columbia, March 26, 2015 /PRNewswire/ ... provided a summary of clinical developments and announced ... Clinical Developments and Anticipated Near-term ... OncoGenex and Teva agreed to negotiate the termination ... OncoGenex. Negotiations of the final termination agreement are ...
(Date:3/26/2015)... S.C. , March 26, 2015 ... told by their existing PACS vendor their system ... (CMH) determined that they needed a better structured ... Hospital selected Avreo interWORKS due to its interface ... modern meaningful use standards through to the hospital,s ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
Plastic Citrate Tube, .109M / 3.2%...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Inquire...
... EDTA K2 / gel tubes are ... for molecular diagnostics and for viral ... whole blood remain stable at room ... For optimal results, it is recommended ...
Medicine Products: